ARPO Aerpio Pharmaceuticals Inc

DGAP-News: Flime Introduces One-Click Contract Execution with Freelancers Around the World

DGAP-News: Flime / Key word(s): Miscellaneous
Flime Introduces One-Click Contract Execution with Freelancers Around the World

06.11.2018 / 09:10
The issuer is solely responsible for the content of this announcement.


Flime Introduces One-Click Contract Execution with Freelancers Around the World

Amsterdam-based startup provides country-specific documents and tax compliance for over 100 countries.

Key takeaways:

  • New online tool that allows for a one-click contract execution with freelancers from more than 100 countries.
  • Provides automated KYC (know your customer) and country-specific tax compliance.
  • Makes payments to bank cards, accounts and electronic wallets internationally.

Amsterdam - November 6, 2018
Flime.com, an Amsterdam-based startup, announces the launch of a new service to manage contracts and payments between companies and freelancers around the world. The online tool provides automated KYC, tax compliance and transfer of copyright. It also makes payments to bank cards, accounts and electronic wallets internationally.

Flime is the only service on the market to provide country-specific tax documents to ensure that both companies and freelancers are 100% compliant in their respective countries. Prior to the launch, Flime ran a year-long research together with Deloitte to check the requirements in each country and guarantee compliance. Each month, Flime's clients and their freelancers receive a complete set of tax and accounting documents online and as a hard copy.

Flime simplifies the workflow: companies sign a single contract with Flime, which acts as their general contractor, instead of having to sign separate agreements with each freelancer. This allows companies to hire as many freelancers as they need and from any countries they choose to.

Flime is compatible and can be integrated into any other solution, including freelance management system, reporting software or project management tool.

Please visit:

For additional information, please contact:

Anna Likhopyorskaya
CEO at Flime

+31(61)5550199
Pavel Shynkarenko
Founder at Flime

+357(99)575977
 


About Flime
Flime is an interface for legal tech & fin tech to manage contracts and payments between companies and freelancers around the world. The online tool provides automated KYC, tax compliance and transfer of copyright, as well as makes payments to bank cards, accounts and electronic wallets internationally. Flime is headquartered in Amsterdam and has external teams on Cyprus, in Russia, Ukraine, Belarus, Latvia and Czech Republic.

 



06.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


741733  06.11.2018 

fncls.ssp?fn=show_t_gif&application_id=741733&application_name=news&site_id=research_pool
EN
06/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch